IRVINE, Calif., Sept. 16 /PRNewswire/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced that it has initiated a Phase 3 clinical program of ISTA's proprietary formulation of REMURA TM ...
Please provide your email address to receive an email when new articles are posted on . IRVINE, Calif. — Ista Pharmaceuticals initiated a new phase 3 program designed to evaluate its proprietary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback